Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

In8Bio Inc (INAB)

In8Bio Inc (INAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,884
  • Shares Outstanding, K 9,847
  • Annual Sales, $ 0 K
  • Annual Income, $ -19,440 K
  • EBIT $ -20 M
  • EBITDA $ -17 M
  • 60-Month Beta 0.00
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.52

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.59
  • Number of Estimates 1
  • High Estimate -0.59
  • Low Estimate -0.59
  • Prior Year -2.10
  • Growth Rate Est. (year over year) +71.90%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3500 +1.48%
on 03/27/26
2.1100 -35.07%
on 03/16/26
-0.3300 (-19.41%)
since 02/27/26
3-Month
1.3500 +1.48%
on 03/27/26
2.7300 -49.82%
on 01/16/26
-0.8600 (-38.57%)
since 12/26/25
52-Week
1.1700 +17.09%
on 12/19/25
5.9370 -76.92%
on 03/31/25
-4.5130 (-76.71%)
since 03/28/25

Most Recent Stories

More News
IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results - Highlights Durable Survival Improvements in Glioblastoma, Advancing Pipeline and Strengthened Financial Position for 2026

Presented updated glioblastoma (“GBM”) data demonstrating durable survival and a favorable safety profile across Phase 1 and Phase 2 programs, with repeat dosing of DeltEx™ Drug-Resistant Immunotherapy...

INAB : 1.3700 (-2.84%)
IN8bio to Present at TD Cowen 46th Annual Health Care Conference

NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc . (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies for cancer and autoimmune...

INAB : 1.3700 (-2.84%)
IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer

NEW YORK, Feb. 09, 2026 (GLOBE NEWSWIRE) -- IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ ) T cell therapies and T cell engagers for cancer...

INAB : 1.3700 (-2.84%)
IN8bio to Present at Upcoming Investor and Scientific Conferences in February

NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc . (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ ) T cell therapies for cancer and autoimmune...

INAB : 1.3700 (-2.84%)
IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma

Repeat-doses of DeltEx™ Drug-Resistant Immunotherapy gamma-delta (γδ) T cells (DRI) nearly doubled median progression-free survival (mPFS) to 13.0 months compared to only 6.6 months (+97%) in a control...

INAB : 1.3700 (-2.84%)
IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager

$20.1 million upfront with a milestone-driven additional $20.1 million to advance INB-619, IN8bio’s novel gamma-delta (“γδ”) T cell engager through an Investigational New Drug (“IND”) application...

INAB : 1.3700 (-2.84%)
IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Presented new preclinical data on INB-619, a novel gamma-delta (γδ) T cell engager (TCE), demonstrating equivalent potency comparable to FDA-approved commercial products with minimal adverse cytokine...

INAB : 1.3700 (-2.84%)
IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site

NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases,...

INAB : 1.3700 (-2.84%)
IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications

INB-619 demonstrated equivalent efficacy to the FDA approved, commercial T Cell Engagers (TCE) compounds, blinatumomab and mosunetuzumab, with minimal adverse cytokine release, highlighting a targeted...

INAB : 1.3700 (-2.84%)
IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications

INB-619 demonstrated equivalent efficacy to the FDA approved, commercial T Cell Engagers (TCE) compounds, blinatumomab and mosunetuzumab, with minimal adverse cytokine release, highlighting a targeted...

INAB : 1.3700 (-2.84%)

Business Summary

IN8bio Inc. is a clinical-stage biotechnology company. It focuses on developing therapies for the treatment of cancers, including solid tumors using allogeneic, autologous, and genetically modified gamma-delta T cells. The company's principal candidate includes INB-200, which are in clinical stage....

See More

Key Turning Points

3rd Resistance Point 1.5833
2nd Resistance Point 1.5367
1st Resistance Point 1.4533
Last Price 1.3700
1st Support Level 1.3233
2nd Support Level 1.2767
3rd Support Level 1.1933

See More

52-Week High 5.9370
Fibonacci 61.8% 4.1160
Fibonacci 50% 3.5535
Fibonacci 38.2% 2.9910
Last Price 1.3700
52-Week Low 1.1700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.